Repligen (NASDAQ:RGEN) Earns Hold Rating from Analysts at Canaccord Genuity Group

Research analysts at Canaccord Genuity Group assumed coverage on shares of Repligen (NASDAQ:RGEN) in a research note issued to investors on Tuesday, MarketBeat.com reports. The brokerage set a “hold” rating and a $165.00 price target on the biotechnology company’s stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 11.99% from the company’s previous close.

A number of other analysts also recently weighed in on RGEN. Canaccord Genuity Group initiated coverage on shares of Repligen in a research report on Tuesday. They issued a “hold” rating and a $165.00 target price on the stock. Wolfe Research initiated coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Wells Fargo & Company initiated coverage on shares of Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price on the stock. Finally, StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and an average price target of $185.20.

Repligen Stock Down 6.8 %

Shares of Repligen stock opened at $147.34 on Tuesday. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The company’s fifty day simple moving average is $143.83 and its two-hundred day simple moving average is $141.78. The company has a market cap of $8.26 billion, a P/E ratio of -398.21, a PEG ratio of 4.64 and a beta of 0.96. Repligen has a 12-month low of $113.50 and a 12-month high of $211.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The business had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.23 EPS. Research analysts anticipate that Repligen will post 1.54 EPS for the current year.

Hedge Funds Weigh In On Repligen

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Andra AP fonden bought a new position in Repligen during the 2nd quarter valued at about $25,000. UMB Bank n.a. lifted its stake in Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 130 shares during the period. Blue Trust Inc. lifted its stake in Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 127 shares during the period. Resources Management Corp CT ADV bought a new position in Repligen during the 3rd quarter valued at about $37,000. Finally, International Assets Investment Management LLC bought a new position in Repligen during the 2nd quarter valued at about $33,000. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.